These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8235783)

  • 1. Life-threatening hyperkalemia associated with captopril administration.
    Doman K; Perlmutter JA; Muhammedi M; Puschett JB
    South Med J; 1993 Nov; 86(11):1269-72. PubMed ID: 8235783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.
    Chan TY; Critchley JA
    Drug Saf; 1992; 7(2):159-61. PubMed ID: 1605901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia.
    Burnakis TG; Mioduch HJ
    Arch Intern Med; 1984 Dec; 144(12):2371-2. PubMed ID: 6391404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Life threatening drug-induced hyperkaliemia--case report].
    Konopa J; Bullo B; Rutkowski B
    Pol Arch Med Wewn; 2006 Mar; 115(3):238-42. PubMed ID: 18468430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperkalemia during prolonged use of angiotensin II-converting enzyme inhibitors in end-stage renal insufficiency].
    Mooser V; Fellay G; Regamey C
    Schweiz Med Wochenschr; 1992 Dec; 122(50):1927-9. PubMed ID: 1465596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?
    Reardon LC; Macpherson DS
    Arch Intern Med; 1998 Jan; 158(1):26-32. PubMed ID: 9437375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Late drug-induced hyperkalemia in a patient with congestive heart failure].
    Konopa J; Bułło B; Rutkowski B
    Przegl Lek; 2005; 62(7):732-3. PubMed ID: 16463712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperkalemia with concomitant watery diarrhea: an unusual association.
    Taylor JG; Zwillich CW; Kaehny WD; Levi M; Popovtzer MM
    Am J Kidney Dis; 2003 Aug; 42(2):E9-12. PubMed ID: 12900845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute tubular necrosis due to captopril.
    Al Shohaib S; Raweily E
    Am J Nephrol; 2000; 20(2):149-52. PubMed ID: 10773617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure.
    Zanella MT; Mattei E; Draibe SA; Kater CE; Ajzen H
    Clin Pharmacol Ther; 1985 Dec; 38(6):613-7. PubMed ID: 2998675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.
    Knoll GA; Sahgal A; Nair RC; Graham J; van Walraven C; Burns KD
    Am J Med; 2002 Feb; 112(2):110-4. PubMed ID: 11835948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
    Schepkens H; Vanholder R; Billiouw JM; Lameire N
    Am J Med; 2001 Apr; 110(6):438-41. PubMed ID: 11331054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-threatening captopril-induced hyperkalemia in a patient on continuous ambulatory peritoneal dialysis.
    Atkin SL; Tomson CR; Venning MC
    Nephrol Dial Transplant; 1989; 4(12):1084. PubMed ID: 2517332
    [No Abstract]   [Full Text] [Related]  

  • 16. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.
    Packer M; Lee WH
    Am J Cardiol; 1986 Feb; 57(4):347-8. PubMed ID: 3004185
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function.
    Garthwaite E; Bhandari S
    Artif Organs; 2009 Aug; 33(8):641-7. PubMed ID: 19624582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergency Department Presentation of Life-threatening Symptomatic Hyperkalemia From an Angiotensin Receptor Blocker in a Low-risk Individual.
    Dockery S; Dupré A; Deflorio P; Murray BP
    Mil Med; 2023 Aug; 188(9-10):3242-3247. PubMed ID: 36454619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperkalemia in the Hypertensive Patient.
    Lakkis JI; Weir MR
    Curr Cardiol Rep; 2018 Mar; 20(2):12. PubMed ID: 29492706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life-threatening hyperkalemia: a potentially lethal drug combination.
    Juvet T; Gourineni VC; Ravi S; Zarich SW
    Conn Med; 2013 Sep; 77(8):491-3. PubMed ID: 24156179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.